Navigation Links
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Date:11/11/2009

ncouraged by this analysis, which demonstrates that adding capecitabine to the chemotherapy regimen in the early stages of breast cancer may prevent the cancer coming back," he added.

Breast cancer is the second most common cancer in the world and the most common cancer among women.[2] There are 1.1 million new cases of female breast cancer each year worldwide.[2] Despite recent advances, there is still an unmet need in the treatment and management of early breast cancer with relapse occurring in approximately 30% of patients, depending on individual risk factors, even after chemotherapy.[3]

Notes to editors:

About the FinXX study

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

    - The primary objective of the study was to compare the
      recurrence-free survival of patients receiving single-agent docetaxel
      (T), followed by cyclophosphamide, epirubicin and 5-FU (CEF) to those
      receiving docetaxel with capecitabine (XT), followed by
      cyclophosphamide, epirubicin and capecitabine (CEX) in the adjuvant
      treatment of early breast cancer.
    - Secondary objectives included the evaluation and comparison
       between the two treatment arms of:
         - Safety profile
         - Overall survival.


    Results to date show that:

    - 54 women in the capecitabine-containing arm had their cancer
      return, or died compared to 80 women in the non-capecitabine
      containing arm of the study.
    - There were fewer deaths among those taking the capecitabine-containing
      combination regimen (a 34% reduction in risk of death was observed in
      this group).
    - 43 wo
'/>"/>
SOURCE The Finnish Breast Cancer Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis
2. Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
5. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
6. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
7. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
8. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
9. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
10. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
11. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... at the,World Congress of Cardiology (WCC), the press ... by John Camm,Professor of Clinical Cardiology, St George,s ... announced ATHENA clinical trial,results, as the way forward ... common form of cardiac arrhythmia., To view ...
... of 2008 --,-- Presentation at the Seventh Annual JMP Securities ... update scheduled during Ardea,s ... --, SAN DIEGO, May 20 Ardea Biosciences, Inc.,(Nasdaq: ... the Company,s,lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating,potent activity ...
Cached Medicine Technology:ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 2Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 4
(Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec ... are thought to have been behind the attack on Anthem Inc. which resulted in ... day exploits, watering hole attacks and spear phishing campaigns. , For Joe ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... , Nurtur Receives ... Nov. 23 The Population Health Impact Institute (PHII), a ... of Directors has approved the Healthcare Transparency Accreditation Program, v ... life, health, and wellness company based in Farmington, CT is ...
... than most friends, relatives or even healthcare professionals realise, according ... issue of the UK-based Journal of Advanced Nursing . ... had undergone surgery in the last year, together with 105 ... years at the Vanderbilt Transplant Center in Tennessee, USA. They ...
... ... Compliance Requirements and Automate Billing, Claims, Enrollment and Eligibility, , ... (PRWEB) November 23, 2009 ... announced today the launch of new products within its healthcare integration suite, designed ...
... both increased risk eightfold , MONDAY, Nov. 23 (HealthDay ... who were exposed to lead have more than double ... other children, new research shows. , And with exposure ... ADHD soared. Children whose mothers smoked during pregnancy and ...
... , SANTA CLARA, Calif., Nov. 23 NewCardio, Inc., (OTC ... CEO, Dr. Branislav Vajdic, and CFO, Richard Brounstein, will present at ... 4:30 PM PST at the Luxe Sunset Hotel in Los Angeles. ... December 2nd and Thursday, December 3rd. Please contact Brett Aimee ...
... ... as Best New Technology Provider for its QlikView Business Intelligence Software , ... Radnor, PA ... company, today announced that it was recognized with the Healthcare IT Innovation™ Award ...
Cached Medicine News:Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 3Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 2Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 3Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 4Health News:Smoking During Pregnancy, Lead Exposure Raise ADHD Risk in Kids 2Health News:Smoking During Pregnancy, Lead Exposure Raise ADHD Risk in Kids 3Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 4
... Left Ventricular Assist System (LVAS), manufactured by ... used as a destination therapy for patients ... heart failure, for which heart transplantation is ... is not intended as a bridge to ...
... The TandemHeart PTVA ( Percutaneous ... unique proprietary solution for the hemodynamic needs ... Cardiologists and Cardiac Surgeons. These specialists ... provide some coronary artery perfusion, but the ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
Medicine Products: